藥物交互作用
Ciltacabtagene autoleucel + Pralatrexate
嚴重程度: 嚴重
Ciltacabtagene autoleucel and Pralatrexate: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Pralatrexate is a myelosuppressive antifolate that can impair the expansion and function of CAR T cells and add to infection risk. Chemotherapy around the time of CAR T infusion can reduce the efficacy of the cell product and worsen cytopenias.
用白話說明這項交互作用的意義
Ciltacabtagene autoleucel and Pralatrexate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ciltacabtagene autoleucel belongs to Miscellaneous; Pralatrexate belongs to Oncology.
為什麼會發生
Cytotoxic and myelosuppressive effects of pralatrexate may reduce CAR T-cell persistence and add to immunosuppression.
處置方式
Avoid pralatrexate around leukapheresis and in the period after CAR T infusion unless clearly needed. Monitor blood counts and screen for infection.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pralatrexate 的其他交互作用
Ciltacabtagene autoleucel 的其他交互作用
常見問題
Can I take Ciltacabtagene autoleucel with Pralatrexate?
MediHelp rates the interaction as major. Ciltacabtagene autoleucel and Pralatrexate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pralatrexate is a myelosuppressive antifolate that can impair the expansion and function of CAR T cells and add to infection risk. Chemotherapy around the time of CAR T infusion can reduce the efficacy of the cell product and worsen cytopenias.
How serious is the interaction between Ciltacabtagene autoleucel and Pralatrexate?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid pralatrexate around leukapheresis and in the period after CAR T infusion unless clearly needed. Monitor blood counts and screen for infection.
What other medicines interact with Pralatrexate?
MediHelp also lists interactions of Pralatrexate with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Brexucabtagene autoleucel. The full list is on the Pralatrexate page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
